NELLA VITA BISOGNA SCEGLiERE TRA GUADAGNARE DENARO E SPENDERLO....
- Creatore Discussione olly®
- Data di Inizio
gasto
Banned
SAN FRANCISCO (MarketWatch) -- Lockheed Martin Corp. /quotes/comstock/13*!lmt/quotes/nls/lmt (LMT 76.81, -0.84, -1.08%) said Wednesday that it will cut 1,200 jobs, or less than 1% of its workforce, in a reoganization of its electronics systems business. Affected employees will be notified by early April. The defense contractor employs about 140,000 people worldwide.
gasto
Banned
@ Bruno dacci un okkio vado a casa son 11 ore in ufficio
a domani
CHKT Stock Quote - Chemokine Therapeutics Corp. Stock Quote - CHKT Quote - CHKT Stock Price
CTI Details
Chemokine Therapeutics Corp., a development-stage company, focuses on the development of peptide-based drugs for human diseases. The company focuses on the area of chemokines, small proteins that regulate various physiological functions primarily in relation to the immune system. Its drug candidates in human clinical trials include CTCE-9908, which is in phase II clinical trials for the treatment of metastasis and angiogenesis cancers; and CTCE-0214 that is in phase I clinical trials stage for hematological support, and for neutrophil, platelet, and stem cell mobilization. The company’s other products comprise CTCE-0422, which is in preclinical development stage for wound healing; and CTCE-0324 that is in preclinical development stage for the treatment of peripheral arterial disease in the areas of neovascularization; and CTCE-0501, which is in preclinical development stage for stroke prevention. In addition, it maintains drug discovery programs to identify new drug candidates. The company, formerly known as PTM Molecular Biosystems, Inc., was founded in 1998 and is headquartered in Vancouver, Canada.
a domani
CHKT Stock Quote - Chemokine Therapeutics Corp. Stock Quote - CHKT Quote - CHKT Stock Price
CTI Details
Chemokine Therapeutics Corp., a development-stage company, focuses on the development of peptide-based drugs for human diseases. The company focuses on the area of chemokines, small proteins that regulate various physiological functions primarily in relation to the immune system. Its drug candidates in human clinical trials include CTCE-9908, which is in phase II clinical trials for the treatment of metastasis and angiogenesis cancers; and CTCE-0214 that is in phase I clinical trials stage for hematological support, and for neutrophil, platelet, and stem cell mobilization. The company’s other products comprise CTCE-0422, which is in preclinical development stage for wound healing; and CTCE-0324 that is in preclinical development stage for the treatment of peripheral arterial disease in the areas of neovascularization; and CTCE-0501, which is in preclinical development stage for stroke prevention. In addition, it maintains drug discovery programs to identify new drug candidates. The company, formerly known as PTM Molecular Biosystems, Inc., was founded in 1998 and is headquartered in Vancouver, Canada.
olly®
DIO E'DONNA!!!
ziozeb
Forumer attivo
V for Vendetta
Carino, molto carino ...
Forse anche di più ...
Mi sa che puoi anche vederlo in streaming:
MEGAVIDEO - I'm watching it
